Argenx

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

2 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Global Markets & Equities 09 Oct 2026, 10:10 AM IST

Argenx Absorbs Celiac Trial Win as It Prepares Pivotal Push for $2.2 Billion Drug

Argenx is leaning into a promising phase 2 readout in celiac disease as it prepares a pivotal development run for its next major growth driver, a program the market has increasingly tied to a multibillion-dollar commercial opportunity. The update comes as investors also weigh a separate setback in another late-stage autoimmune study, underscoring both the promise and volatility of the company’s expanding immunology pipeline.

By RDU Global Wire4 min read

Global Markets & Equities09 Oct 2026, 06:38 PM IST

Argenx Digests Celiac Disease Win as $2.2 Billion Vyvgart Bet Faces New Scrutiny

Argenx is trying to turn a phase 2 celiac disease win into momentum for its flagship Vyvgart franchise, even as investors reassess the drugmaker after a late-stage setback in Sjögren’s disease. The company’s latest data point supports a broader autoimmune expansion strategy, but the market is now weighing whether the pipeline can absorb the blow from a discontinued study and still justify the valuation attached to its multibillion-dollar ambitions.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Argenx:

Washington, D.C.(2)Vyvgart(2)United States(1)Federal Reserve(1)